In today’s session Mylan NV (MYL) recorded an unusually high (1,249) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious MYL decrease. With 1,249 contracts traded and 59224 open interest for the Nov, 16 contract, it seems this is a quite bearish bet. The option with symbol: MYL161118P00037500 closed last at: $1.76 or 12% down. About 1.97M shares traded hands. Mylan NV (NASDAQ:MYL) has declined 17.19% since April 8, 2016 and is downtrending. It has underperformed by 22.84% the S&P500.
Mylan NV (NASDAQ:MYL) Ratings Coverage
Out of 16 analysts covering Mylan Inc. (NASDAQ:MYL), 10 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 63% are positive. $85 is the highest target while $46 is the lowest. The $59.80 average target is 51.58% above today’s ($39.45) stock price. Mylan Inc. has been the topic of 27 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Argus Research given on Friday, August 7. The stock of Mylan NV (NASDAQ:MYL) has “Buy” rating given on Friday, November 13 by Citigroup. RBC Capital Markets maintained the shares of MYL in a report on Tuesday, September 6 with “Sector Perform” rating. Leerink Swann maintained Mylan NV (NASDAQ:MYL) on Wednesday, May 4 with “Outperform” rating. Barclays Capital initiated the stock with “Equal Weight” rating in Monday, September 21 report. The firm has “Buy” rating by UBS given on Monday, October 10. Wells Fargo initiated the shares of MYL in a report on Friday, February 19 with “Market Perform” rating. The stock of Mylan NV (NASDAQ:MYL) has “Overweight” rating given on Wednesday, November 18 by JP Morgan. The firm earned “Buy” rating on Wednesday, August 19 by BTIG Research. Leerink Swann maintained the shares of MYL in a report on Saturday, August 29 with “Outperform” rating.
According to Zacks Investment Research, “Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.”
Insitutional Activity: The institutional sentiment decreased to 0.45 in Q2 2016. Its down 0.05, from 0.5 in 2016Q1. The ratio worsened, as 6 funds sold all Mylan NV shares owned while 5 reduced positions. 1 funds bought stakes while 4 increased positions. They now own 533,685 shares or 37.96% less from 860,251 shares in 2016Q1.
Icon Advisers Co last reported 35,000 shares in the company. Princeton Portfolio Strategies Group Ltd Limited Liability Company holds 1.89% of its portfolio in Mylan NV (NASDAQ:MYL) for 135,477 shares. The California-based Jacobs Company Ca has invested 0.07% in Mylan NV (NASDAQ:MYL). Gulf Comml Bank (Uk) Limited reported 123,183 shares or 0.09% of all its holdings. Novare Mngmt Llc has 79,851 shares for 0.93% of their US portfolio. Covington Capital Mgmt has 0.16% invested in the company for 39,339 shares. Amer Research Mngmt last reported 1,600 shares in the company. The West Virginia-based Ntv Asset Mgmt Limited Liability Corp has invested 0.26% in Mylan NV (NASDAQ:MYL). The Florida-based Eagle Asset Mngmt has invested 0.02% in Mylan NV (NASDAQ:MYL). Westport Resource Management Incorporated last reported 0.37% of its portfolio in the stock. Vantage Inv Advsr Ltd Co accumulated 712 shares or 0.01% of the stock. The California-based Gemmer Asset Limited Company has invested 0% in Mylan NV (NASDAQ:MYL).
Mylan N.V. is a global pharmaceutical company. The company has a market cap of $21.10 billion. The Firm develops, licenses, makes, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients . It has a 77.29 P/E ratio. It operates through two divisions: Generics and Specialty.
MYL Company Profile
Mylan N.V., incorporated on July 7, 2014, is a global pharmaceutical company. The Firm develops, licenses, makes, markets and distributes generic, branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). The Firm operates through two divisions: Generics and Specialty. The principal markets for Generics are pharmaceutical wholesalers and distributors; group purchasing organizations; drug store chains; independent pharmacies; drug manufacturers; institutions, and public and governmental agencies primarily within the United States and Canada (collectively, North America); Europe, and India, Australia, Japan, New Zealand and Brazil (collectively, Rest of World). The Generics segment also focuses on developing API with non-infringing processes for both internal use and to partner with manufacturers in regulated markets, such as the United States and the European Union at market formation. The principal market for Specialty is pharmaceutical wholesalers and distributors, pharmacies and healthcare institutions primarily in the United States.
More notable recent Mylan NV (NASDAQ:MYL) news were published by: Fool.com which released: “Acquisitions and International Sales Growth Help Mylan NV in Q3” on November 09, 2016, also Businessinsider.com with their article: “EpiPen-maker Mylan whiffs on earnings” published on November 09, 2016, Schaeffersresearch.com published: “Earnings Preview: Mylan NV and AstraZeneca plc” on November 09, 2016. More interesting news about Mylan NV (NASDAQ:MYL) were released by: Businesswire.com and their article: “Glancy Prongay & Murray LLP Commences Investigation on Behalf of Mylan NV …” published on November 03, 2016 as well as Investorplace.com‘s news article titled: “Mylan NV (MYL) Stock Holders Can Shrug Off Kaleo’s EpiPen Threat” with publication date: October 27, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.